Targeted Radionuclide Therapy With <scp> ¹³¹ I </scp> ‐Labeled Anti‐ <scp>PD</scp> ‐ <scp>L1</scp> Antibody Suppresses Pharyngeal Squamous Cell Carcinoma in the Animal Model

Collectively, our findings demonstrate the promising therapeutic potential of ¹³¹I-aPD-L1 for PSCC, particularly in patients with drug resistance or recurrent head and neck tumors. However, the use of nude mice may have impacted the full therapeutic efficacy and synergistic potential observed with immunotherapy. Future studies should utilize immunocompetent models to better assess the probe's therapeutic impact and to explore its synergistic effects with immunotherapy and reduce the dose of ¹³¹I to mitigate its toxic effects.